FREE MEMBERSHIP Includes » ABL Advisor eNews + iData Blasts | JOIN NOW ABLAdvisor Gray ABLAdvisor Blue
Skip Navigation LinksHome / News / Read News


Trinity Capital Provides $60MM in Growth Capital to Metabolon

May 16, 2024, 08:03 AM
Filed Under: Life Sciences

Trinity Capital announced the commitment of $60 million in growth capital to Metabolon, a global leader in providing metabolomics solutions advancing a wide variety of life science research, diagnostic, therapeutic development, and precision medicine applications.

Metabolon develops scientific, technological, and bioinformatics techniques to measure inputs from internal and external factors such as health, disease, nutrition, microbiome, medication, and environmental exposure, to help answer scientific questions about health and disease. Metabolon's customizable metabolomics solutions support research in the biopharma, population health, consumer products, agriculture, wellness, academic, and government sectors, across the research continuum.

"We are excited to partner with Metabolon, a company that has demonstrated innovation and excellence in the life sciences sector," said Rob Lake, Senior Managing Director, Life Sciences at Trinity. "By leveraging their cutting-edge technology and extensive experience, the team has the potential to accelerate research and we look forward to supporting the company's ongoing growth and expansion in the industry."

This new growth capital will allow Metabolon to expand its research and development efforts to further enhance its metabolomics platform. The investment will also support the company's global expansion plans, including market penetration initiatives and strategic partnerships.

"We are extremely pleased to announce this successful financing with Trinity, marking a significant milestone for Metabolon. This infusion of additional capital and robust process leading up to it underscore the strong investor confidence in Metabolon's vision, capabilities, and market potential within the multiomics and metabolomics industry" said Rohan (Ro) Hastie Chief Executive Officer at Metabolon. "As the life sciences embrace a sophisticated multiomics paradigm, Metabolon is emerging as an industry benchmark and an essential catalyst toward achieving true precision medicine. This investment will enable us to accelerate growth, drive innovation, and further solidify our position as a leader in the metabolomics space."

Comments From Our Members

You must be an ABL Advisor member to post comments. Login or Join Now.